Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ATR | Q13535 | 2/20 | 0.78 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.76 |
| ▸ | MTOR | P42345 | 5/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-1390 SCHEMBL18631972 | 1.00 | ATM (1.00) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL18631990 | 0.99 | ATM (0.98) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL18631991 | 0.98 | ATM (0.95) | ATMKCNH2ATRPIK3CAMTOR | |
| Azd-1390 SCHEMBL21800798 | 0.93 | ATM (0.87) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL29565981 | 0.90 | ATM (0.81) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL18632000 | 0.90 | ATM (0.81) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL25989795 | 0.89 | ATM (0.80) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL29565832 | 0.89 | ATM (0.80) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL18631934 | 0.89 | ATM (0.80) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL20844074 | 0.88 | ATM (0.79) | ATMKCNH2ATRPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110431139-B | Deuterated imidazo [4,5-c ] quinolin-2-one compounds and their use in treating cancer | 阿斯利康(瑞典)有限公司 | 2022-07-05 | — | — | CN | claimed |
| EP-3683220-B1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF HUNTINGTON'S DISEASE | ASTRAZENECA AB (SE) | 2022-04-13 | — | — | EP | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025109076-A1 | BIOMARKERS FOR IDENTIFYING PATIENTS HAVING TUMORS WITH HOMOLOGOUS RECOMBINATION DEFICIENCY | INSTITUT CURIE (FR) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025088175-A1 | ALC1 INHIBITORS FOR USE IN TREATING CANCER BY POTENTIATING THE EFFECTS OF SEVERAL CLASSES OF APPROVED CANCER DRUGS | EISBACH BIO GMBH (DE) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025056741-A1 | AZD1390, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN COMBINATION WITH RADIATION FOR USE IN A METHOD OF TREATMENT OF A CNS TUMOUR | ASTRAZENECA AB (SE) | 2025-03-20 | — | — | WO | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-114920728-B | Methylisoindigo derivative and preparation method and application thereof | 中南大学 | 2023-10-20 | — | — | CN | disclosed |
| US-20230044248-A1 | COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER | ARES TRADING S.A. (CH) | 2023-02-09 | — | — | US | disclosed |
| CN-114920728-A | Methylidine derivative and preparation method and application thereof | 中南大学 | 2022-08-19 | — | — | CN | disclosed |
| CN-110431139-B | Deuterated imidazo [4,5-c ] quinolin-2-one compounds and their use in treating cancer | 阿斯利康(瑞典)有限公司 | 2022-07-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230044248-A1 | COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER | ATM, PDCD1, CD274 | ATM 1/4885KCNH2 4453/4885ATR 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.